The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
Telehealth giant Hims & Hers has abruptly stopped offering its newly launched compounded version of Novo Nordisk's Wegovy pill amid FDA scrutiny. The decision follows constructive industry conversations, raising questions about compounded GLP-1 availability. Patients seeking semaglutide for weight management now face shifting options.
Taiwan's Food and Drug Administration (FDA) has reported 21 cases of suspected adverse reactions to GLP-1 receptor agonists like Ozempic used for weight loss. Symptoms include gastrointestinal disorders, hypoglycemia, nausea, and more. Amid global concerns from US lawsuits and UK pancreatitis warnings, the FDA urges doctor-prescribed use only.
Experts are sounding the alarm on a 'worrying' surge in dangerous weight-loss 'jab hacks' like microdosing Wegovy or sourcing from beauty therapists. A survey shows 32% of UK users microdose and 28% buy unlicensed drugs amid rising costs. Discover the real risks and expert advice for safe use.
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
A senior South African Police Service official admitted under oath to asking her boyfriend's company for Ozempic amid pharmacy shortages. Brigadier Rachel Matjeng's testimony at the Madlanga Commission highlights the drug's high demand for type 2 diabetes and off-label weight loss use. The case raises questions about procurement ethics in a corruption inquiry.
Tennis icon Serena Williams has shared her inspiring weight loss story, dropping 34 pounds with GLP-1 drugs after struggling post-retirement and motherhood. Facing unknown heart disease risks, she credits the medication with transforming her health. Inside her journey and how GLP-1 works for real results.
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
